EGFR and non-small cell lung carcinoma: Osimertinib, the third generation EGFR-TKI, is increasingly being used as a first-line treatment for advanced NSCLC with EGFR mutation and has also been recommended by Chinese Society of Clinical Oncology (CSCO) guidelines in China (Wang et al., 2021).